Gabriel Mannis, MD

Hematologist-oncologist

Clinics

Cancer Immunotherapy Clinic
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Phone for Existing Patients: (415) 353-2421
Phone for New Patients: (415) 353-2051

Hours: Monday to Friday, 8 a.m. – 5 p.m.

Hematology and Blood and Marrow Transplant
400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051
Fax: (415) 353-2467

Hours: Monday to Friday, 8 a.m. - 5 p.m

Board Certification

Internal Medicine, American Board of Internal Medicine

Academic Title

Assistant Professor

More about Gabriel Mannis

Education

University of California Davis School of Medicine 2008

Residencies

UCSF Medical Center 2011

Fellowships

UCSF Medical Center 2014

Selected Research and Publications

  1. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 02.
  2. Mannis GN. Discussion on reply to Foley et al., 'Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?' Cancer Genet. 2018 Jan; 220:77-78.
  3. Foley N, Van Ziffle J, Yu J, Qi Z, Grenert JP, Yeh I, Bastian B, Kogan S, Mannis GN. Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation? Cancer Genet. 2017 Oct; 216-217:74-78.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.